Previous Close | 1.2900 |
Open | 1.3200 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 57.50 |
Expire Date | 2025-01-17 |
Day's Range | 1.2700 - 1.3200 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.
FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.